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Serum-free mouse embryo (SFME) cells, which were derived
 
from 16-day-old Balb/c mouse embryo brain,  grow in absence of
 
serum without losing genomic normality or proliferative
 
potential, and require epidermal growth factor  (EGF)  for
 
normal growth. EGF is a well studied mitogen that binds  to a
 
specific receptor on the cell surface membrane to activate
 
the proliferative signal transduction pathways. The activated
 
receptor is a tyrosine specific protein kinase, and tyrosine
 
phosphorylation is one of the important mediators of EGF
 
receptor (EGFR) signal transduction.
 
Using anti-phosphotyrosine Western immunoblotting,  we
 
detected a 100 kDa protein which is tyrosine-phosphorylated
 
in  response  to  EGF  in  SFME  cells.  This  protein  is
 
constitutively phosphorylated in an SFME cell line which
 
expresses the neu oncogene. The neu oncogene encodes an
 
analog protein of EGFR which does not require  a ligand for
 
activation, and neu-transformed SFME cells are tumorgenic in
 
mice.This protein, p100 was not a fragment of EGFR, and was
 
not antigenically related to  other signal  transduction
 
phosphoproteins of about 100 kDa. We attempted to purify p100
 
from neu SFME tumor cells for amino acid sequencing.
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 Purification and Identification of  a  100 kDa Protein,
 
Which is Tyrosine-Phosphorylated by EGF Stimulation
 
in SFME Cells
 
Chapter  1.  Introduction
 
Serum-free mouse embryo (SFME) cells, which were derived
 
from 16-day-old Balb/c mouse embryo brain,  grow in the
 
absence  of  serum without  losing  genomic normality  or
 
proliferative potential,  unlike conventional mouse embryo
 
cells in serum-supplemented media. SFME cells are cultured in
 
a rich basal medium supplemented with insulin, transferrin,
 
epidermal growth factor  (EGF),  high density lipoprotein
 
(HDL),  and fibronectin  (Loo et al.,  1987).  SFME cells in
 
vitro express the intermediate filament protein nestin  (Loo
 
et al.,  1994),  a marker for neuroepithelial stem cells in
 
vivo (Lendahl et al., 1990), and express astrocytic markers,
 
including glial  fibrillary acidic protein and glutamine
 
synthetase, when exposed to transforming growth factor beta
 
or  cytokines  acting  through gp130  (Loo  et  al.,  1995;
 
Nishiyama et al., 1993; Sakai et al., 1990; Solem et., 1990;
 
Weisz et al.,  1993). Cells with properties similar in some
 
respects to SFME can be isolated from human embryonic brain
 
(Loo et al., 1991).
 
SFME cells require EGF for normal growth, and die within
 
48 hours without EGF (Loo et al., 1987; Rawson et al., 1990;
 
Abbreviations: SFME, Serum-free mouse embryo; EGF, epidermal
 
growth factor; EGFR, EGF receptor; TGF, transforming growth
 
factor; FGF, fibroblast growth factor; bFGF, basic FGF; SH2,
 
Src  homology  2;  PLC,  phospholipase  C;  PIP2,
 
phosphatidylinositol 4,5-bisphosphate; DAG, diacylglycerol;
 
IP3, inositol 1,4,5-triphosphate; PKC, protein kinase C; PY,
 
phosphotyrosine.
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Rawson et al., 1991). Transforming growth factor alpha (TGF­
alpha), which also binds to EGF receptor, can substitute EGF
 
although it is not as effective as EGF, and fibroblast growth
 
factor (FGF) can partially replace EGF (Loo et al., 1989). On
 
the  other hand,  SFME  cell proliferation  is  reversibly
 
inhibited by serum or platelet-free plasma  (Loo et  al.,
 
1987). SFME cells transformed with the human Ha-ras  or rat
 
neu oncogene or expressing the protooncogene bc1-2 no longer
 
require EGF for survival (Shirahata, et al.,  1990; Loo, et
 
al., 1997). The acute dependence of SFME cells on EGF and the
 
ability to grow the cells in the absence of growth factors
 
present in serum provides an uncomplicated way to examine EGF
 
signaling and the relationship of growth factor signaling to
 
apotosis in vitro.
 
EGF is a well-studied mitogen of 53 amino acids with
 
molecular mass of 6 kDa. Although the early studies revealed
 
that EGF stimulates the proliferation of epithelial cells in
 
vivo  (Carpenter and Cohen,  1990),  subsequently numerous
 
biological activities on various tissues have been reported,
 
some of them apparently unrelated to mitogenesis  (see the
 
list by Carpenter an Wahl,  1990; also refer to Fisher and
 
Lakshmanan,  1990).  EGF also shows mitogenic activity for
 
various types of cultured cells in vitro.
 
Is has been suggested that EGF plays an important role
 
in brain development. Neurogenesis in the mammalian central
 
nervous  system  (CNS)  mostly  occurs  during  embryonic
 
development,  and ends shortly after birth  (Reynolds and
 
Weiss, 1992). EGF receptor (EGFR) is known to be expressed in
 
mouse embryo brain, and its expression increases dramatically
 
during day 15 to 19.  (Adamson and Meek, 1984). Many in vitro
 
studies indicate that EGF has various effects on CNS nerve
 
cells,  such as proliferation of embryonic and neonatal
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retinal cells of rat  (Anchan et al.,  1991), generation of
 
neurons and astrocytes from mouse embryonic striatal cells
 
(Reynolds et al.,  1992) and adult striatal cells (Reynolds
 
and Weiss,  1992), and mitogenic activity in the olfactory
 
epithelium of neonatal rat  (Mahanthappa and Schwarting,
 
1993). However, mechanisms by which growth factors, including
 
EGF,  promote brain development  in vivo are still to be
 
studied.
 
EGF binds tightly to a specific transmembrane receptor
 
on the cell surface membrane (Carpenter and Cohen,  1990;
 
Fisher and Lakshmanan,  1990). The EGFR,  or c-erbB-1 gene
 
product,  is  a 170 kDa glycoprotein,  divided into three
 
domains: a cysteine-rich extracellular domain to which the
 
ligand binds,  a transmembrane domain which consists of
 
hydrophobic amino acids, and a cytoplasmic domain which has
 
tyrosine kinase activity. The cytoplasmic domain is  also
 
divided into two parts;  a tyrosine kinase domain and a
 
carboxyl-terminal tail with tyrosine residues which  are
 
autophosphorylated  subsequent  to  the  ligand  binding.
 
Phosphorylation of tyrosine residues is  one of the most
 
important mediators in signal transduction, not only of  EGFR,
 
but also of many pathways of other growth factors (Glenney,
 
1992).
 
Generally, the EGF monomer is considered to bind to EGFR
 
monomer in stoichiometry of 1  1, and this binding causes a
 :
 
conformational  change  of  the  receptor  resulting  in
 
dimerization and kinase activation,  although there is  a
 
report that one EGF molecule binds to two receptor molecules
 
(Lemmon and Schlessinger, 1994). The kinase of each monomer
 
in the receptor dimer phosphorylates the other  on tyrosine
 
residues at the carboxyl termini, and also phosphorylates
 
several other cytoplasmic proteins.  The phosphotyrosine
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Figure 1.  Signal transduction pathways of EGFR
 
See the text for abbreviations.  non-protein
 
molecules;  non-phosphotyrosine proteins;
 CD
  :
 
phosphotyrosine proteins;
  negative regulations.
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residues are recognized by proteins which have Src homology 2
 
(SH2) domains to activate proliferative pathways (Figure 1.
 
Also see the reviews by Ullrich and Schlessinger, 1990; and
 
Schlessinger and Ullrich, 1992).
 
The most well-studied pathway subsequent to receptor
 
tyrosine  kinase  activation  by  ligand  binding  is  the
 
Ras/Raf/MEK/ERK pathway (See the reviews by Blenis,  1993;
 
Marshall, 1995). One of the phosphotyrosine residues in the
 
cytoplasmic domain of EGFR is recognized by the SH2 domain of
 
the Grb2 adaptor protein, which constitutively binds to Sos,
 
a Ras guanine nucleotide exchange factor (Egan et al., 1993;
 
Ruff-Jamison et al., 1993a; Ravichandran et al.,  1995). Ras
 
is inactive when binding to GDP, and active when binding to
 
GTP, and Sos activates Ras by exchanging GDP to GTP. Another
 
adaptor protein Shc is known to bind to EGFR, and both EGFR-

Shc-Grb2-Sos and EGFR-Grb2-Sos complexes have been reported
 
(Buday and Downward, 1993; Sasaoka et al, 1994). On the other
 
hand,  GAP  (GTPase activating protein)  works as negative
 
regulator, enhancing the GTPase activity of Ras. GAP and its
 
two associated proteins,  p62  and p190 are known to be
 
tyrosine-phosphorylated through EGF-dependent mechanism
 
(Ellis et al.,  1990; Cantley et al., 1991). Active Ras-GTP
 
recruits cytoplasmic protein Raf to the plasma membrane, and
 
Raf is activated by a still unknown factor. Although the
 
mechanism of Raf activation is unclear,  phosphorylation
 
primarily of serine residues is thought to be involved (Daum
 
et  al.,  1994).  Raf itself  is  also a serine kinase and
 
activates MEK (MAP kinase/ERK-activating kinase), which is  a
 
"dual-specificity protein  kinase",  activating  another
 
protein,  ERK  (extracellular signal-regulated kinases)  by
 
phosphorylating threonine and tyrosine residues. ERK, which
 
is  a  serine/threonine kinase,  enters  the nucleus,  and
 
phosphorylates  transcription  factors  for  early  gene
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expression. In addition, cytoplasmic protein RSK (ribosomal
 
protein S6 kinase)  is also activated by ERK through serine
 
and/or threonine phosphorylation, and enters the nucleus to
 
stimulate early gene transcription.
 
A second pathway involves phospholipase C-gamma (PLC­
gamma). The PLC-gamma molecule has two src homology 2  (SH2)
 
domains, and binds to the cytoplasmic domain of EGFR. PLC-

gamma, activated by EGFR through tyrosine-phosphorylation,
 
cleaves phosphatidylinositol 4,5-bisphosphate (PIP2)  in the
 
cell membrane to generate diacylglycerol (DAG) and inositol
 
1,4,5-triphosphate  (IP3).  DAG is an activator of protein
 
kinase C  (PKC),  and  IP3  induces calcium ion  flux from
 
endoplasmic  reticulum  (ER)  to  cytoplasm  (Ullrich  and
 
Schlessinger, 1990; Schlessinger and Ullrich, 1992).
 
PKC is  a serine/threonine kinase,  and plays complex
 
roles in signal transduction. It is known that PKC negatively
 
regulates EGFR through threonine phosphorylation (Morrison et
 
al., 1996). However, at present, at least 11 members of PKC
 
have been reported. These can be divided in to three classes:
 
classical PKC (cPKC) including PKC-alpha, beta I, beta II and
 
gamma; novel PKC (nPKC) including PKC-delta, epsilon, eta and
 
theta;  and atypical  PKC  (aPKC)  including PKC-zeta and
 
iota/lambda. Each member shows different characteristics. For
 
example,  cPKCs are Ca2+ dependent, but nPKCs are not, and
 
aPKCs are not activated by Ca2+ or DAG (Stahel and Parker,
 
1991; Akimoto et al.,  1996). There have been reports that
 
cPKCs activate Raf as positive regulators of the EGFR signal
 
transduction  (Sozeri et al.,  1992;  Kolch et al.,  1993).
 
Therefore, more detailed studies in each PKC member seem to
 
be necessary.
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Recently, a distinctively different Jak-STAT pathway was
 
proposed. This pathway was originally discovered in studies
 
of interferon (IFN)-alpha and gamma signal transduction (See
 
the reviews by Darnell et al., 1994; Ihle et al., 1994). Jak
 
(Janus kinase) proteins have tyrosine kinase function  as
 
indicated by their name, and also must be phosphorylated  on
 
their own tyrosine residues for enzyme activation.  STAT
 
(signal transducers and activators of transduction) proteins
 
have SH2  domains  to recognize phosphotyrosine,  and are
 
tyrosine-phosphorylated by active Jaks.  In the example of
 
IFN-alpha, when the ligand binds to its receptor, two types
 
of Jak proteins, Jakl and Tyk2 bind to the cytoplasmic domain
 
of the receptor. Tyrosine-phosphorylated active Jakl and Tyk2
 
phosphorylate  tyrosine  residues  of  STAT1  and  STAT2
 
respectively.  STAT1 and STAT2 are translocated into the
 
nucleus where they form a heterodimer through each other's
 
SH2 domains and phosphotyrosine residues. This heterodimer
 
binds to a specific ISRE  (interferon-stimulated response
 
element)  sequence in early genes,  involving another DNA
 
binding protein p48. In the case of IFN-gamma, Jakl and Jak2
 
bind to the receptor, then STAT1 homodimer binds  to GAS (IFN­
gamma activation site) without p48. At present, at least 3
 
Jaks (Jakl, Jak2 and Tyk2) and 4 STATs (STAT1, STAT2, STAT3
 
and STAT4) have been reported and Jakl, STAT1 and STAT3  are
 
known to be involved in EGFR signal transduction. However,
 
most of the details of this pathway are still to be studied,
 
including whether some other accessary proteins are involved.
 
Other  possible  pathways  exist  for  EGF  signal
 
transduction. Phosphatidylinositol 3-kinase (PI3K) has been
 
reported to bind to EGFR, and be activated through tyrosine­
phosphorylation. However, this is still controversial because
 
EGFR lacks the specific sequence in its carboxyl tail for
 
PI3K binding (Cantley et al., 1991; Soltoff et al, 1994).  In
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addition, two other EGFR substrates, Eps8 and Eps15 have been
 
reported, the involvement of these proteins in EGF-related
 
pathways remain to be elucidated (Fazioli et al., 1993a and
 
b; Alvarez et al., 1995).
 
Using  Western  blotting with  anti-phosphotyrosine
 
monoclonal antibody, we detected a protein with molecular
 
mass approximately 100 kDa which is tyrosine-phosphorylated
 
in  SFME  cells  in  response  to  EGF.  This  protein  is
 
constitutively phosphorylated, with  or without EGF,  in a
 
transgenic SFME cell line which expresses the  neu oncogene
 
(Shirahata, et al., 1990) and is tumorigenic in mice.
 
The neu oncogene produces an analog protein of the  EGFR
 
gene although they are distinct genes  (See the review by
 
Dougall et al., 1994). The neu oncogene codes for  a 185 kDa
 
protein and is oncogenically activated from the protooncogene
 
(cellular neu or c-neu, also called c-erbB-2) by  a point
 
mutation. It is known that amplification and overexpression
 
of c-neu (c-erbB-2) as well as mutation to its oncoform can
 
lead to malignant transformation (Guy et al., 1992 and 1996),
 
and similar results  are  obtained with EGFR  (c-erbB-1)
 
(Mendelsohn and Gabriolove, 1995; Stumm et al.,  1996). The
 
physiological function of Neu in normal cell growth and
 
tissue development is still unclear. There have been reports
 
of Neu expression in fetal and adult tissues, including fetal
 
brain.
 
Currently, at least 4 members of the EGFR family have
 
been identified: EGFR(ErbB-1), neu(ErbB-2), ErbB-3, and ErbB­
4. Like the EGFR, the Neu onco and protooncoproteins have  a
 
extracellular domain, a transmembrane domain (the site of the
 
point mutation), and a cytoplasmic domain which has tyrosine
 
kinase activity (Dougall, et al., 1993). The point mutation
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in the transmembrane domain allows dimerization and  tyrosine
 
kinase activation of the oncoprotein without ligand.  It has
 
been  discovered  that  EGFR  family  members  can  form
 
heterodimers,  and properties of these receptors such  as
 
ligand binding,  signal  transduction,  and physiological
 
function,  now seem to be more complex than previously
 
thought.
 
Several potential ligands for the Neu protooncoprotein
 
have been reported, but the relationships  among these ligands
 
and members of the receptor family are not yet clear. Neither
 
of the EGFR ligands, EGF or TGF-alpha bind to Neu. Heregulin,
 
originally thought to be a Neu ligand is more likely a ligand
 
of Erb-3 and -4. Results are complicated because Neu can be
 
activated through heterodimerization with ErbB-3  or  -4
 
(Lemmon and Schlessinger, 1994).
 
Difference in signal transduction between EGFR and Neu
 
has been suggested because of low homology of amino acid
 
sequence between the carboxyl-terminal tails for the two
 
proteins. These tails are important for substrate binding.
 
However, no specific substrate for either has been reported.
 
There is a possibility that EGFR/Neu heterodimer activates  a
 
pathway distinct  from that  of  either  the  EGFR or Neu
 
homodimers.
 
In this project, we characterized the 100 kDa protein,
 
which  is  tyrosine-phosphorylated  specifically  by  EGF
 
stimulation, and attempted to purify and identify by amino
 
acid sequencing.  This  is  a  first step toward precisely
 
defining the role of this protein in EGF signaling pathways
 
and the mechanisms of EGF action in brain development  and
 
oncogenesis.
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Chapter  2.  Materials and Methods
 
1. Materials
 
1.1  Cell culture and cell lysis
 
Dulbecco's modified Eagle medium (D-MEM), F-12 nutrient
 
mixture (Ham),  and HEPES were obtained from Gibco BRL/Life
 
Technologies (Gaithersbug, MD). Sodium bicarbonate and sodium
 
selenite were obtained from Fisher Scientific  (Fair Lawn,
 
NJ). Penicillin,  streptomycin, ampicillin, bovine insulin,
 
human  transferrin,  heparin,  trypsin,  soybean  trypsin
 
inhibitor,  and other chemicals were obtained from Sigma
 
Chemical (St. Louis, MO). High-density lipoprotein (HDL)  was
 
prepared as described by Gospodarowicz (1984) and Loo et al.
 
(1989). Mouse epidermal growth factor (EGF) and human basic
 
fibroblast growth factors (bFGF) were obtained from Upstate
 
Biotechnologies (Lake Placid, NY). Fetal bovine  serum (FBS)
 
was obtained from HyClone Laboratories (Logan, UT).
 
Nonident  P-40,  sodium ortho-vanadate,  all protease
 
inhibitors  including  aprotinin,  peps tat in  A,
 
phenylmethylsulfonylfluoride (PMSF), leupeptins and antipain,
 
and other chemicals were obtained from Sigma Chemicals.
 
1.2  SDS-PAGE, Western blotting and silver staining
 
The apparatus for electrophoresis and Western blotting
 
for  8  x  10 cm  (H x W)  gels were obtained from Bio-Rad
 
Laboratories (Hercules, CA).
 
Acrylamide (acrylamide  N-N'-methylenebisacrylamide =
 :
 
29:1),  sodium dodecyl sulfate  (SDS),  ammonium persulfate,
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N,N,N',N'-tetramethylenediamine  (TEMED), protein molecular
 
weight  standards,  and Silver Stain Kit  for gel  silver
 
staining were obtained from Bio-Rad Laboratories. Bromophenol
 
blue (BPB) was obtained from Sigma Chemical. Polyvinylidene
 
difluoride  (PVDF)  membrane for Western immunoblotting was
 
obtained from Millipore (Bedford, MA).
 
Anti-phosphotyrosine monoclonal antibody,  sheep anti­
human EGF receptor (EGFR) polyclonal antibody, rabbit anti­
human STAT1 polyclonal antibody, and rabbit anti-human B-Raf
 
polyclonal  antibody  were  obtained  from  Upstate
 
Biotechnologies. Goat anti-mouse IgG horseradish peroxidase
 
conjugate and Goat anti-rabbit IgG horseradish peroxidase
 
conjugate were obtained from Bio-Rad Laboratories. Rabbit
 
anti-sheep IgG horseradish peroxidase conjugate was obtained
 
from Cappel (West Chester, PA). ECL kit and Hyperfilm-MP were
 
obtained from Amersham Life Science (Cleveland, OH).
 
1.3  Protein purification
 
Anti-phosphotyrosine Immunoaffinity Purification Kit was
 
obtained from Upstate Biotechnologies. Centriflo CF50A for
 
protein concentration was obtained from Amicon (Beverly, MA).
 
Thioglycolic acid was obtained from Sigma.  SYPRO Orange
 
protein dye used to estimate the proteins' positions in
 
polyacrylamide gels was obtained from Bio-Rad. For protein
 
elecctroelution form polyacrylamide gels,  I used the Elutrap
 
kit by Schleicher and Schuell (Keene, NH).
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1.4  Preparation for amino acid sequencing
 
3-[cyclohexalamino]-1-propanesulfonic acid  (CAPS)  was
 
obtained from Sigma Chemical. Coomassie Brilliant Blue (CBB)
 
G-250 was obtained from Bio-Rad.
 
2. Methods
 
2.1  Cell culture
 
SFME cells were derived from the neural stem cells of
 
16-day-old Balb/c embryo and grown in the serum-free culture
 
medium as described by Loo et al.  (1987, 1989). The serum-

free culture medium was prepared as below:  a one-to-one
 
mixture of D-MEM and Ham's f-12 was supplemented with 1.5  mM
 
HEPES,  pH 7.4,  1.2  g/L sodium bicarbonate,  200  U/ml
 
penicillin, 200 µg /ml streptomycin and 25 µg /ml ampicillin
 
(F12:DME). Immediately before the cells were plated, F12:DME
 
was supplemented with 10 µg /ml bovine insulin, 40 µg /ml human
 
transferrin, 10 µg /ml human HDL, 10 nM sodium selenite and 50
 
ng/ml mouse EGF (supplemented serum-free medium).
 
For Western immunoblotting, the cells were replated  on
 
30 mm dishes in the density of  1 x 106 cells in 2 ml of
 
supplemented serum-free medium per dish  (with or without
 
EGF). The cells were grown under the following conditions
 
before cell lysis: for 5 hours without EGF or bFGF (-EGF,
 
bFGF),  for  5  hours with EGF  (+EGF,  -bFGF),  for  5  hours
 
without EGF or bFGF followed by 10 minutes with EGF (-/+EGF,
 
-bFGF), for 5 hours with FGF (-EGF, +bFGF),  or for 5 hours
 
without EGF or bFGF followed by 10 minutes with FGF(-EGF,­
/+bFGF). Heparin was also added to the medium when bFGF was
 
added in order to enhance the effect of bFGF (Loo et al.,
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1989); the concentrations of bFGF and heparin were 10 ng/ml
 
and 1 µg /ml respectively.
 
NIH 3T3 cells were grown in 10  % FBS in F12:DME. For
 
Western blotting,  the cells were replated in 30 mm dishes
 
containing F12:DME with 10 % FBS  (1 x 106 cells /2 ml), and
 
were harvested 5 hours later.
 
A431 human carcinoma cell lysate was supplied by Upstate
 
Biotechnology as a positive control of human STAT1 and human
 
B-Raf.
 
2.2  Transgenic SFME cells
 
SFME cells were transfected with human Ha-ras or rat neu
 
oncogene as described by Shirahata et al.  (1990).
 
2.3  Cell lysis
 
The lysis buffer for extraction of cytoplasmic proteins
 
was 20 mM Tris-HC1, 100 mM NaC1, 20 mM sodium ortho-vanadate,
 
1.0  % Nonident P-40, pH 7.4. Protease inhibitors  (5  lag/m1
 
aprotinin,  1  µg /ml pepstatin A,  1  µg /ml  PMSF,  1  µg /ml
 
leupeptins, and 1 gg/m1 antipain) were added to the lysis
 
buffer immediately before cell lysis (Sambrook, et al. 1989).
 
The lysis buffer was spread on the dishes immediately
 
after the medium was removed (200 gl buffer/1 x 106 cells/30
 
mm dish). Lysate from each dish was collected in an Eppendolf
 
tube after lysis was confirmed microscopically. Optimal lysis
 
occurred after 1-2 minutes. The tubes were centrifuged at
 
12,000 x g for 10 minutes to remove cellular debris, and the
 
supernatants were transferred to fresh tubes.
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The lysates were stored at -80 degree C.  Samples were
 
thawed and again centrifuged at 12,000 x g for 10 minutes
 
before fractionation by SDS-PAGE.
 
2.4  SDS-PAGE, Western blotting and silver staining
 
SDS-PAGE gels were generated using 375 mM Tris-HC1, 6.0
 
%  acrylamide  (acrylamide  :  N-N'-methylenebisacrylamide  =
 
29:1), 0.1 % SDS, 0.05 % ammonium persulfate, 0.5 % TEMED, pH
 
8.8. The stacking gel was 125 mM Tris-HC1, 4.0 % acrylamide,
 
0.1 % SDS,  0.05 % ammonium persulfate, 1.0% TEMED, pH 6.8.
 
Samples were prepared in 50 mM Tris-HC1,  1.0  % SDS,  0.1 %
 
BPB,  10 % glycerol, 100 mM  dithiothritol (DTT), pH 6.8, and
 
boiled for  5  minutes.  Electrophoresis was performed in
 
running buffer containing 25 mM Tris-HC1, 192 mM glycine, 0.1
 
%  SDS,  pH 8.3,  at  30 mA/gel.  For separation of  large
 
proteins,  the samples were run until prestained marker
 
proteins of approximate 50 kDa migrated to the bottom of the
 
gels. Buffer for Western blotting was 25 mM Tris-HC1, 192 mM
 
glycine,  20 % methanol, pH 8.3. Proteins were blotted onto
 
PVDF membrane at 100 V for 1 hour or at 30 V overnight. The
 
blotted membrane was washed with phosphate buffered saline
 
(PBS)  containing 0.05  %  Tween-20  (Washing Buffer),  and
 
blocked with  1.0  %  BSA  in  Washing  Buffer  for  anti­
phosphotyrosine immunostaining, or with 3.0 % dried skim milk
 
in Washing Buffer for anti-EGFR, anti-Stat1, or anti-B-Raf
 
immunostaining. The membrane was incubated with the primary
 
antibody at the vendor's recommended dilution, and with the
 
secondary antibody at 1:6000 dilution in 1.0 % BSA in Washing
 
Buffer.  Excess  antibodies were washed  out  after  each
 
incubation. Western blot signals were detected with an ECL
 
kit according to the manufacturer's directions.
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Silver staining was also performed according  to the
 
manufacturer's directions.
 
2.5  Protein electroelution from acrylamide gels
 
Samples were concentrated with Centriflo CF50A to
 
approximately 200 Rl. SDS-PAGE was performed  as described for
 
Western blotting except that the samples were prepared in a
 
sucrose sample buffer (62.5 mM Tris-HC1, 2.0 mM EDTA, 3.0 %
 
SDS,  100 mM sucrose, 100 mM DTT, pH 6.9), and heated at 60
 
degree C for 15 minutes, instead of the glycerol buffer and
 
boiled for 5 minutes. In addition 0.1 mM thioglycolic acid
 
was added on the top of the running buffer before the samples
 
were applied to scavenge reactive compounds that would
 
interfere with amino acid sequencing.
 
Position of proteins in the polyacrylamide gels were
 
estimated by molecular size markers stained for 20 minutes
 
with SYPRO Orange in the SDS-PAGE running buffer, and area of
 
the gel containing each protein were cut out and placed in an
 
Elutrap  chamber.  The proteins  were  eluted  in  buffer
 
containing 15 mM NH4CO3,  0.1 % SDS, pH 8.2,  for  4 hours,
 
following directions supplied by Schleicher and Schuell.
 
2.6  Preparation for Amino acid sequencing
 
Samples were concentrated by lyophilizing. SDS-PAGE was
 
performed  as  described  for  protein  purification.
 
Electroblotting was performed as  described  for Western
 
blotting except a CAPS buffer (10 mM CAPS, 10 % methanol,  pH
 
11.0)  was used instead of the Tris-glycine buff
 
blotted PVDF membranes were stained in 0.25 % CBB
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methanol,  and partially destained in  50  %  methanol  to 
visualize the proteins. 18 
Chapter 3.  Results
 
1. Detection and characterization of p100
 
SFME cells were grown in 5 different conditions: without
 
EGF or bFGF for 5 hours (-EGF, -bFGF); with EGF for 5 hours
 
(+EGF, -bFGF); without EGF or bFGF for 5 hours followed by 10
 
minutes with EGF (-/+EGF, -bFGF); with bFGF (-EGF, +FGF); and
 
without EGF or bFGF for 5 hours followed by 10 minutes with
 
bFGF (-EGF, -/+bFGF). Cytoplasmic proteins were extracted as
 
described in Materials and Methods. Each sample was boiled
 
for 10 minutes immediately after cell lysis to inactivate
 
residual proteases and analyzed by anti-phosphotyrosine(PY)
 
Western immunoblotting. The result is shown in Figure 2. No
 
difference was observed among the three conditions:  -EGF,
 
bFGF (lane 1); -EGF, +FGF (lane 4); and -EGF, -/+bFGF (lane
 
5). In contrast, +EGF, -bFGF (lane 2) and -/+EGF, -bFGF (lane
 
3)  showed  two  growth  factor-dependent  bands:  one  at 
approximately 170 kDa, which is the size of EGFR,  and the 
other at 100 kDa. 
A similar experiment was performed with human Ha-ras and
 
rat neu oncogene transformed SFME cells. The result of ras
 
SFME cells  is  shown in Figure  3;  ras SFME cells showed
 
additional bands not seen in untransformed SFME cells, but
 
significant differences were not observed among  the
 
different conditions used to identify growth factor-dependent
 
phosphorylation. Although some response to EGF could be seen
 
in lane  3  (-/+EGF,  -bFGF),  it was much weaker than the
 
response of untransformed SFME cells  (Figure 2,  lane 3).
 
Phosphorylation of p100 was difficult to evaluate in ras SFME
 
cells because many fine bands appeared between 80 and 120
 
kDa.
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Figure 2. Anti-phosphotyrosine Western immunoblot of
 
untransformed SFME cells. Samples were boiled for 10 minutes
 
to inactivate proteases immediately after cell lysis.  Samples
 
were adjusted to represent equal cell numbers in all lanes.
 
Numbers indicate molecular mass references. EGFR and p100 are
 
indicated with arrows.
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Figure 3. Anti-phosphotyrosine Western immunoblot of ras
 
oncogene transformed SFME cells. Samples were boiled for 10
 
minutes to inactivate proteases immediately after cell lysis.
 
Samples were adjusted to represent equal cell numbers in all
 
lanes. Numbers indicate molecular mass references.  EGFR and
 
p100 are indicated with arrows.
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Results with neu SFME cells are shown in Figure 4. neu
 
SFME cells in all  5 conditions showed an SFME-like pattern
 
when cultured -/+EGF, -FGF (lane 3, Figure 2). Additionally,
 
a strong band was detected above the EGFR band. We assumed
 
that this band is the Neu oncoprotein, p185. The EGFR and
 
p100 were detected in all conditions with or without EGF. The
 
EGFR appeared a little stronger in lane 2  (+EGF, -bFGF), and
 
more so  in lane  3  (-/+EGF,  -bFGF).  The p100 band also
 
appeared a little stronger in lane 3,  indicating a response
 
to EGF.
 
After ligand binding,  the EGFR is  internalized and
 
transported to lysosomes for degradation (Carpenter and Wahl,
 
1990) and proteolytic degradation products of the EGFR have
 
been observed in other laboratories in experiments similar to
 
those described above. Therefore it was necessary to examine
 
the possibility that p100 was  a  fragment  of  EGFR.  We
 
performed Western immunoblotting of the samples with an anti­
human  EGFR  polyclonal  antibody  that  recognizes  the
 
cytoplasmic domain of EGFR and has cross reactivity with
 
mouse EGFR. The anti-EGFR antibody detected only a band at
 
170 kDa, consistent with our identification of the band as
 
the EGFR and suggesting that proteolytic degradation was
 
successfully avoided in our protocol (Figure 5) and that p100
 
is not a frayment of EGFR.
 
The time course of tyrosine phosphorylation in p100 was
 
examined. SFME cell were lysed after 5,  10,  and 15 minutes
 
after EGF administration, and compared on a Western blot.
 
Figure  6  shows that tyrosine phosphorylation reaches a
 
maximum at about 5 minutes, then declines.
 
Our results indicated that p100 might be a protein which
 
is tyrosine-phosphorylated through activation of the EGFR
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Figure 4. Anti-phosphotyrosine Western immunoblot of neu
 
oncogene transformed SFME cells. Samples were boiled for 10
 
minutes to inactivate proteases immediately after cell lysis.
 
Samples were adjusted to represent equal cell numbers in all
 
lanes. Numbers indicate molecular mass references. EGFR, Neu
 
and p100 are indicated with arrows.
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Figure 5. Anti-EGF receptor Western immunoblot of
 
untransformed and neu oncogene transformed SFME cells.
 
Samples were boiled for 10 minutes to inactivate proteases
 
immediately after cell lysis. Samples were adjusted to
 
represent equal cell numbers in all lanes. Numbers indicate
 
molecular mass references. EGFR is indicated with an arrow.
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Figure 6. Time course of tyrosine phosphorylation by EGF
 
stimulation in untransformed SFME cells. Samples were not
 
boiled after cell lysis. Samples were adjusted to represent
 
equal cell numbers in all lanes. Numbers indicate molecular
 
mass references. EGFR and p100 are indicated with arrows.
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(and possibly also Neu), and we postulated that the protein
 
may be involved in EGF signal transduction within the cell. A
 
search of databases and the literature for EGF-dependent
 
tyrosine-phosphorylated  proteins  did  not  identify  a
 
previously studied candidate for p100 observed in other
 
laboratories. Thus, we decided to purify and identify this
 
protein by amino acid sequencing.
 
2. Tumor production to harvest p100
 
A major problem was encountered in our attempts to
 
purify the protein.  The p100,  like many other candidate
 
signal proteins, exists at low concentration in cells, and it
 
became evident that isolation of the protein from cultured
 
SFME cells  in amounts sufficient  for primary structure
 
analysis was not practical. To provide sufficient material
 
for the protein isolation, we used the procedure described
 
below.
 
The approximately lx107 neu SFME cells suspended in
 
F12:DME medium (total volume about 200 gl)  were injected
 
under the epidermis of the left shoulder of a Balb/c moused.
 
The mouse was killed 2-3 weeks later when the  neu SFME cells
 
formed a visible tumor, and the tumor was excised for protein
 
extraction as described below.
 
After fatty tissue and blood were washed out with
 
F12:DME medium,  the neu tumor was minced and incubated in
 
F12:DME medium containing 50 ng/ml EGF for 5 minutes. The
 
tumor cells were centrifuged and medium removed. The cell
 
pellet was then incubated in the lysis buffer described
 
above. The tumor was extracted at 4 degree C overnight, then
 
the buffer was removed the next day.  This procedure was
 
repeated  five  times  (five  days)  to  complete  protein
 
extraction.  For these preparations,  we did not boil the
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extracts, because a major portion of the proteins in the
 
extracts,  including  phosphotyrosine  proteins,  were
 
precipitated by the boiling.
 
We compared the neu tumor extract and untransformed SFME
 
and neu SFME cell extracts by anti-phosphotyrosine Western
 
immunoblot (Figure 7). The tumor extract (lane 5)  showed a
 
very similar pattern to neu SFME cells in -/+EGF,  -bFGF
 
condition (lane 4), except the two bands at 130-140 kDa and
 
90 kDa appeared stronger in the tumor extract. Because no
 
additional bands  were detected near p100, we concluded that
 
this neu tumor extract could be used for p100 purification.
 
We used three Balb/c mice for tumor production.
 
3. p100 purification
 
Our purification procedure involved three steps: Step 1,
 
the lysis buffer adjustment; Step 2,  anti-PY immunoaffinity
 
chromatography; and Step 3,  separation of the protein by
 
preparative SDS-PAGE and electroelution.
 
In Step 1 we varied the concentration of salt, chelator,
 
detergent and tyrosine phosphatase inhibitors, starting with
 
the  formulation suggested by the vendor  for  the Anti­
phosphotyrosine Immunoaffinity Purification Kit. This buffer
 
contains 20 mM Tris-HC1,  10 mM EDTA,  100 mM NaC1,  1  %
 
Nonident P-40, 0.2 mM sodium ortho-vanadate (Na3VO4), pH 7.4.
 
Ortho-vanadate is a inhibitor of phosphatases, and we raised
 
its concentration to 20 mM for additional protection of
 
phosphotyrosine residues without adverse effect  on  the
 
extraction.  Our goal was maximal extraction of the EGF-

responsive p100 with minimal extraction of constitutively
 
phosphorylated phosphotyrosine proteins.
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Figure 7. Anti-phosphotyrosine Western immunoblot of
 
untransformed and neu oncogene transformed SFME cells, and
 
neu-SFME tumor cell extract. Samples were not boiled after
 
cell lysis. Samples of the untransformed and neu SFME cells
 
were adjusted to represent equal cell numbers in all lanes.
 
Numbers indicate molecular mass references. EGFR, Neu and
 
p100 are indicated with arrows.
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Figure 8. Anti-phosphotyrosine Western immunoblot of
 
untransformed SFME cells (+EGF, -bFGF) in different NaC1
 
concentration and with or without 10 mM EDTA. Samples were
 
boiled for 10 minutes to inactivate proteases immediately
 
after cell lysis. Samples were adjusted to represent equal
 
cell numbers in all lanes. Numbers indicate molecular mass
 
references. EGFR and p100 are indicated with arrows.
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Final  results  of  experiments examining effects  of
 
changes in concentration of NaC1 and EDTA on phosphoprotein
 
extraction are shown in Figure 8. Here we examined extraction
 
of untransformed SFME  (+EGF,  -bFGF) using anti-PY Western
 
blotting. The samples were boiled for 10 minutes immediately
 
after the cell lysis. We examined samples extracted with or
 
without 10 mM EDTA, and with 10, 100, 200 or 500 mM NaCl. 100
 
or 200 mM NaCl without EDTA (lanes 2 and 3,  respectively)
 
showed the strongest p100 signal.  We chose 100 mM NaC1
 
because we were concerned that further raising the NaC1
 
concentration  might  affect  protein  binding  in  the
 
immunoaffinity chromatography. Removing EDTA had no effect on
 
the chromatography. The final formula of the lysis buffer was
 
20 mM Tris-HC1, 100 mM NaC1,  1 % Nonidet P-40, 20 mM Na3VO4,
 
pH 7.4.
 
Anti-PY immunoaffinity chromatography was performed as
 
suggested by the vendor of the column material. The lysate
 
was loaded on the column followed by washing with the lysis
 
buffer, and phosphotyrosine proteins were eluted with 100 mM
 
phenylphosphate in the lysis buffer. Binding and elution were
 
confirmed with anti-PY Western blot.
 
The eluate fractions were pooled, and the phosphoprotein
 
band pattern compared by anti-PY Western immunoblotting and
 
in silver staining. As seen in Figure 9, protein stain and
 
phosphoprotein signal showed similar patterns, indicating a
 
major purification of phosphotyrosine proteins had occurred,
 
and p100 appeared as a discrete band in silver staining. We
 
also noticed another discrete band at approximately 95 kDa,
 
which showed almost the same intensity as p100 in silver
 
staining,  although  it  was  barely  detected  in  the
 
phosphotyrosine immunoblot. This protein is likely minimally
 
phosphorylated, and may be a dephosphorylation product of
 
p100. It is well established that proteins change mobility in
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Figure 9. neu tumor extract before and after anti­
phosphotyrosine affinity chromatography. A: anti­
phosphotyrosine Western immunoblot of eluate after
 
chromatography. B: silver staining of samples before and
 
after chromatography. EGFR, Neu, p100 and p95 are indicated
 
with arrows.
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gel  electrophoresis  with  the  degree  of  tyrosine
 
phosphorylation  (Huang et al.,  1995;  Yan and Templeton,
 
1994). For these reasons, we decided to isolate p95 as well
 
as p100.
 
The next step was designed to separate p100 and p95 from
 
the  other phosphotyrosine proteins in the eluate. The eluate
 
was  concentrated with Centriflo CF50A, then run on SDS-PAGE.
 
The  gels were stained with SYPRO Orange protein dye, which
 
does  not  interfere with subsequent  electroblotting  or
 
electroelution,  and has relatively high sensitivity. Even
 
after concentration, the amounts of p100 and p95 were not
 
high enough to be visualized with the dye.  Therefore we
 
estimated the positions  of these proteins in the gel using
 
stained molecular mass  references.  Areas containing both
 
proteins  in the gels was cut out,  and electroeluted as
 
described  in Materials  and Methods.  Purification was
 
monitored with Western blotting and silver staining (Figure
 
10), and indicated that both proteins had been successfully
 
isolated with minimal contamination.
 
4. Two candidates of p100: STAT1 and B-Raf
 
While carrying out this project,  we identified two
 
candidates for p95 or p100 from the literature. One is STAT1
 
(p91), which is known to be tyrosine-phosphorylated through
 
EGF stimulation (Fu and Zhang,  1993; Ruff-Jamison et al.,
 
1993;  Silvennoien  et  al.,  1993).  We performed Western
 
blotting using anti-human STAT1 polyclonal antibody which
 
recognizes the carboxyl terminal of STAT1 and has  cross-

reactivity with mouse.  Figure  11  shows  the result  of
 
analyzing the anti-PY immunoaffinity chromatography eluate by
 
anti-PY and anti-STAT1 Western blot. All samples were loaded
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Figure 10. p100 and p95 after separation in SDS-PAGE and
 
electroelution. A: anti-phosphotyrosine Western immunoblot.
 
B: silver staining.
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Figure 11. Anti-phosphotyrosine(PY) and anti-STAT1 Western
 
immunoblots of identical samples. Identical amounts of each
 
sample were loaded for both blots. Samples were not boiled
 
after cell lysis. Samples were adjusted to represent equal
 
cell numbers of SFME and NIH 3T3 cells. All samples were
 
loaded on one gel. After SDS-PAGE and electroblotting, the
 
PVDF membrane was cut in halves. The left half was
 
immunostained for anti-PY, and the right immunostained for
 
anti-STAT1. Numbers indicate molecular mass references. EGFR,
 
Neu, p100 and STAT1 are indicated with arrows.
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on one gel, and the same amount of each sample was used for
 
both blotting. After SDS-PAGE and electroblotting, the  PVDF
 
membrane was cut in half, and one set of samples  was stained
 
with anti-PY, while the other was stained with anti-STAT1
 
antibody. A431 and NIH 3T3 are positive controls of human and
 
mouse STAT1 respectively, and both showed a STAT1 signal.
 
Other bands  (possibly due to degradation or nonspecific
 
binding)  were seen,  depending on tissue and cell  line.
 
Positive controls were as expected, but the PY protein eluate
 
or crude extract of SFME cells with or without EGF showed  no
 
signal. We concluded that neither p100 nor p95 is STAT1, and
 
that STAT1 is not tyrosine-phosphorylated through  an EGF
 
signal in SFME cells.
 
The other candidate is B-Raf. At present,  at least  3
 
isoforms of Raf have been identified in vertebrates:
  c-Raf
 
(p73), A-Raf (p68) and B-Raf (p94-97)  (Daum et al., 1994).
 
Storm et al.  (1990) reported that B-raf is expressed in high
 
levels especially in fetal brain,  and adult cerebrum and
 
testes while c-raf and A-raf are expressed ubiquitously in
 
both fetal and adult tissues. Wixler et al.  (1996) reported
 
that B-Raf is activated in response to EGF. Although the main
 
phosphorylation sites on Raf proteins  are thought be serine
 
residues, reports of tyrosine or threonine phosphorylation
 
exist (Heidecker et al., 1992; Daum et al., 1994). We carried
 
out Western blotting using anti-human B-Raf polyclonal
 
antibody which recognizes the carboxyl terminal of B-Raf  and
 
has cross-reactivity with mouse. The result is  shown in
 
Figure 12. Anti-PY and anti-B-Raf Western blottings  were
 
performed as described for anti-STAT1 Western blotting. A431
 
and adult mouse brain extract are used as human and mouse B-

Raf positive controls. Mouse brain was extracted with the
 
lysis buffer used for SFME cells and neu tumors. Both A431
 
and mouse brain showed a strong signal at approximately 105
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Figure 12. Anti-phosphotyrosine(PY) and anti-B-Raf Western
 
immunoblots of identical samples. Identical amounts of each
 
sample were loaded for both blots. Samples were not boiled
 
after cell lysis. Samples were adjusted to represent equal
 
cell numbers of SFME and NIH 3T3 cells. All samples were
 
loaded on one gel. After SDS-PAGE and electroblotting, the
 
PVDF membrane was cut in halves. The left half was
 
immunostained for anti-PY, and the right immunostained for
 
anti-B-Raf. Numbers indicate molecular mass references  EGFR,
 
Neu, p100 and B-Raf are indicated with arrows.
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kDa, and we assumed this band to be B-Raf, because Moodie et
 
al.  (1994) reported that they detected B-Raf at 95-105 kDa.
 
NIH 3T3 showed a fine signal at 105 kDa, but the PY protein
 
eluate did not show this signal. We concluded that neither
 
p100 nor p95  is B-Raf,  and that B-Raf  is not tyrosine­
phosphorylated in respond to EGF in SFME cells. We also did
 
not detect B-Raf in crude extracts of the untransformed and
 
neu SFME cells, with or without EGF, despite our expectation
 
that it might be present in these fetal brain derived cells
 
(Figure 13). These results indicated that p95 or p100 might
 
be novel EGF-responsive proteins, possibly involved in signal
 
transduction, and protein sequencing should proceed.
 
5. Amino acid sequencing of p95 and p100
 
We were unable to sequence the samples through the
 
facility of Oregon State University because of the small
 
amount of material obtained (about 10 pmol). One sample was
 
sent to a sequencing facility of Purdue University. Because
 
we were uncertain if these proteins could be sequenced by
 
methods  and  equipment  available  in  most  academic
 
institutions,  we  first  sent  the  less  critical  p95
 
electroeluate. However, p95 could not be sequenced because it
 
could not be directly blotted on a PVDF membrane because of
 
SDS in the electroelution buffer. The sample was returned to
 
our laboratory, and electroblotted and visualized by CBB on a
 
membrane as described in Materials and Methods. We sent the
 
membrane to Purdue again, and it still could not be sequenced
 
because of its amount, either because the amino acid terminal
 
is  blocked or because of  the  small amount  of protein
 
remaining after these procedures. However, because p95 could
 
be visualized by CBB on the membrane after electroblotting,
 
there is still a possibility that it can be sequenced. We are
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Figure 13. Anti-B-Raf Western immunoblots. Samples were not
 
boiled after cell lysis. Samples were adjusted to represent
 
equal cell numbers of untransformed SFME, neu SFME and NIH
 
3T3 cells. Numbers indicate molecular mass references. B-Raf
 
is indicated with an arrow.
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searching for another institute which has more sensitive
 
equipment.
 39 
Chapter  4.  Discussion
 
1. Detection and characterization of p100
 
Using anti-phosphotyrosine  (PY) Western immunoblotting
 
we detected a protein with molecular size of approximately
 
100 kDa which is tyrosine-phosphorylated by EGF stimulation
 
of SFME cells. The tyrosine phosphorylation of this protein,
 
which we call p100, was EGF specific (not observed upon bFGF
 
stimulation), occurred with or without EGF in neu  oncogene
 
transformed SFME cells. The neu oncogene produces an EGFR-

analog protein which is constitutively active without ligand
 
binding. Thus, we speculated that p100 could be a signal
 
protein involved with either or both EGFR and Neu.
 
We examined also ras oncogene transformed SFME cells.
 
However, because ras SFME cells showed many additional bands
 
in Western blots than untransformed or neu SFME cells did,  we
 
couldn't determine if p100 is tyrosine-phosphorylated by EGF
 
in these cells. Since Ras is in the middle of the signal
 
transduction pathways,  overexpression of active Ras may
 
induce massive activation of downstream signal proteins. Ras
 
activation may also lead to negative feedback regulation,
 
such as threonine phosphorylation of EGFR and phosphatase
 
activation by MAPK (Griswold-Prenner et al.,  1993; Morrison
 
et al.,  1993)  so that the whole picture is difficult to
 
dissect.
 
We  did  not  detect  any  bFGF  specific  signal  in
 
untransformed SFME cells by anti-PY Western blotting. It is
 
established that bFGF  is  one  of  the  FGFs which  show
 
angiogenic activity in vivo, as well as mitogenic activity in
 
various types of mesoderm and neuroectoderm derived cells in
 
vitro. Like EGFR, FGF receptor (FGFR)  is a tyrosine kinase
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receptor,  and the  ligand binding induces dimerization,
 
tyrosine kinase activation and tyrosine phosphorylation at
 
the carboxyl tail. Regarding signal transduction, it is known
 
that FGFR activates PLC-gamma. At present, at least five FGFR
 
genes have been identified,  and each of  them expresses
 
proteins with various size, affinity to FGFR and tyrosine
 
kinase activity.  The receptors with high affinity and
 
tyrosine kinase activity are in the range of 110-150 kDa
 
(Burgess and Maciag, 1989; Jaye et al., 1992).
 
Although bFGF has shown mitogenic activity in SFME
 
cells,  it is not as effective as EGF  (Loo et a.,  1989).
 
Probably FGFR is expressed and activated in SFME cells, but
 
not  sufficiently so  to be detected in anti-PY Western
 
blotting.
 
We suspected that p100 might be a degraded fragment of
 
the  EGFR  because  it  was  always  strongly  tyrosine­
phosphorylated when the EGFR was phosphorylated and because
 
after EGFR binding, the EGFR is transported to lysosome for
 
degradation (Carpenter and Wahl,  1990). However, anti-EGFR
 
polyclonal antibody did not recognize p100 or any other EGFR
 
derived proteolytic products in our samples, suggesting that
 
p100 is not the result of EGFR degradation. The EGFR signal
 
was weaker with EGF in the untransformed and neu SFME cells
 
because EGF accelerates the receptor's internalization and
 
transportation to lysosome (Carpenter and Wahl,  1990). The
 
EGFR seems to be expressed much less in neu SFME cells than
 
the untransformed SFME cells.  The active Neu oncoprotein
 
and/or EGFR activated by heterodimerization with Neu may
 
induce the feedback negative regulation.
 
We also found two candidates for p100 based on molecular
 
size and EGF-responsive tyrosine phosphorylation.  One of
 
these, STAT1  (p91),  is known to be tyrosine-phosphorylated
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through EGF stimulation (Fu and Zhang, 1993; Ruff-Jamison et
 
al.,  1993b; Silvennoien et al.,  1993). However, we did not
 
detect STAT1 in the phosphotyrosine protein eluate of the
 
anti-phosphotyrosine affinity chromatography, which contained
 
only PY proteins Therefore, we concluded that p100 is not
 
STAT1, and that STAT1 is not activated by EGF in SFME cells.
 
Although we did not detect STAT1 in the crude extract of the
 
untransformed  SFME  cells,  with  or  without  EGF,  these
 
experiments do not allow us to conclude if the SFME cells  are
 
expressing STAT1. Usually signal proteins exist in very small
 
amount in cells,  so sometimes they are difficult to detect
 
with direct Western blotting using antibody to the protein,
 
as we did in this project. This can be true even when using
 
the very sensitive ECL detection method. Overloading samples
 
may exceed the PVDF membrane's capacity, so, to determine if
 
SFME cells are expressing STAT1, we would have to perform
 
STAT1 immunoprecipitation before Western blotting.
 
The  other  candidate was  B-Raf  (p94-97).  B-raf is
 
reported to be expressed specifically in fetal brain as well
 
as adult cerebrum and testes of normal mice, while c-raf and
 
A-raf, which produce 73 kDa and 68 kDa proteins respectively,
 
are expressed ubiquitously (Storm et al.,  1990). This was
 
especially of interest because SFME cells were derived from
 
mouse embryonic brain. Although two serine residues are
 
considered to be the major phosphorylation sites of B-Raf,
 
there have been some reports  of  threonine or  tyrosine
 
phosphorylation (Heidecker et al., 1992; Daum et al., 1994).
 
B-Raf kinase activity can be stimulated by EGF, although it
 
is not clear if tyrosine phosphorylation is required in this
 
activation (Wixler, et al. 1996). The phosphotyrosine protein
 
eluate did not show a B-Raf signal, suggesting that p100 is
 
not B-Raf, and that B-Raf is not tyrosine-phosphorylated by
 
EGF in the SFME cells. We also did not detect B-Raf in crude
 
extracts of the untransformed and neu SFME cells, with or
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without EGF, despite our expectation that it might be present
 
in these fetal brain derived cells. However, we can not be
 
certain that SFME cells are expressing B-Raf for the same
 
reason we described above for STAT1.
 
2. Tumor production to harvest p100
 
The p100 protein,  like many other signal proteins,
 
exists in very small amount in each cell so that harvesting
 
enough for amino acid sequencing from SFME cells is not
 
practical. Instead we turned to isolation from tumors derived
 
from neu SFME cells injected under the epidermis of a Balb/c
 
mouse.  Tumor became visible 2-3 weeks after injection.
 
Cytoplasmic proteins from the tumor cells were extracted with
 
the same lysis buffer used for cultured SFME cells,  and the
 
anti-PY Western blot showed a very similar pattern to the neu
 
SFME cells.
 
3. p100 purification
 
The lysis buffer was adjusted in the beginning of this
 
project  for  maximal  harvest  of  p100  while minimizing
 
contamination with other phosphoproteins. In the beginning,
 
we boiled the samples to ensure the protease and phosphatase
 
inactivation; later we ceased boiling because it precipitated
 
a significant amount of proteins including p100, and we also
 
found that the enzyme inhibitors added in the lysis buffer
 
seemed to be working sufficiently. We attempted to minimize
 
NaCl concentration because this might affect p100 protein
 
binding in the affinity chromatography, and also, because 500
 
mM NaC1 can dissociate the nuclear membrane,  releasing
 
additional phosphoproteins as well as DNA and RNA,  may
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interfere with the chromatography. Because removing EDTA did
 
not affect on the chromatography results, our final formula
 
contained 100 mM NaC1 without EDTA.
 
Once  the  lysis buffer  formulation was  determined,
 
phosphotyrosine proteins were isolated from the neu tumor
 
cell  lysate using the anti-PY affinity chromatography.
 
Purification was monitored by Western blotting and silver
 
staining.  In addition to p100,  we detected a strong and
 
discrete band at approximately 95  kDa,  which is barely
 
detected in anti-PY Western blot. We speculated that p95 has
 
less phosphotyrosine residues than p100,  and results as
 
described above indicated that it is unlikely to be STAT1 or
 
B-Raf.  We  do  not  know  at  this  time  if  p95  tyrosine
 
phosphorylation is EGF-specific, because p95 signal is too
 
week to detect by Western blotting for phosphotyrosine, but
 
the possibility exists that p95 might be related to p100
 
(i.e.,  the same protein with less phosphorylated tyrosine
 
residues). It is known that tyrosine phosphorylation changes
 
protein mobility in SDS-PAGE (Huang et al.,  1995; Yan and
 
Templeton, 1994).
 
The p100  and p95 proteins were separated on SDS­
polyacrylamide  gel,  then  cut  out  from  the  gel  and
 
electroeluted  as  described  in  Materials  and Methods.
 
Purification was confirmed with Western blotting and silver
 
staining. The purified p95 was easily detected with anti-PY
 
Western blotting.
 
4. Amino acid sequencing and possible future experiments
 
The p95 and p100 proteins have not been sequenced.
 
Assuming sufficient sequence can be obtained, the next step
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will be to search for proteins that have  an identical or
 
similar sequence with molecular size of p100  in protein
 
databases. If we can not find such proteins in any databases,
 
it would be more likely a novel protein, and we would try to
 
identify mRNA of the protein in the SFME cells using  a
 
synthetic (degenerate) probe predicted from the amino acid
 
sequence. If mRNA is successfully probed, the next step would
 
be to clone the cDNA and sequence clones to determine the
 
entire coding sequence of the gene.
 
Even  in the absence of  sequence,  some information
 
regarding the nature of p95 and p100 can be obtained from
 
determination of the amino acid compositions. If the protein
 
can not be sequenced due to the small amount, alternative
 
approaches will be required to produce enough material for
 
sequencing. We may make antibody by making hybridomas after
 
immunizing mice by injection of the protein directly into
 
mouse spleen in collaboration with investigators at the
 
University of Oregon Monoclonal Antibody Facility. We could
 
then  purify  p100  using  antibody  in  immunoaffinity
 
chromatography (with or without tyrosine phosphorylation)
 
from Balb/c mice brain or other tissues. The antibody also
 
could be used for more characterization of the protein, such
 
as  tissue  specificity  of  expression  and  subcellular
 
localization.
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